Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Haemophilus influenzae type b is a rare cause of adult lobar pneumonia and we are unaware of any reported British cases. However in the United States this condition is well described and the incidence is increasing (Levin et al. 1977).
 ...
PMID:Lobar pneumonia caused by Haemophilus influenzae type B. 387 75

A clinical trial of bacampicillin was carried out in 20 patients. The antibiotic was found to be effective in acute lobar pneumonia, pyogenic meningitis, acute and chronic bronchitis, acute pharyngitis, acute tonsillitis, cellulitis, furunculosis, and pyomyositis caused by such ampicillin-sensitive organisms as Neisseria meningitidis, Diplococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pyogenes, Klebsiella pneumoniae, and Escherichia coli. Rash in three patients was the only side effect encountered. It is concluded that while bacampicillin may have overcome some of the disadvantages of ampicillin, it retains its main attributes and some shortcomings.
 ...
PMID:Clinical trial of bacampicillin in acute bacterial infections. 635 33

Haemophilus influenzae is an uncommon but important cause of lobar pneumonia, specifically in patients whose host defence mechanisms are impaired by unrecognized underlying diseases. A case of H. influenzae lobar pneumonia in a patient with underlying multiple myeloma is presented. The clinical features, treatment and procedures which aid in making the diagnosis are briefly discussed.
 ...
PMID:Haemophilus influenzae lobar pneumonia with underlying multiple myeloma: a case report. 696 27

Studies on antimicrobial activity, absorption and excretion and clinical use of cefoxitin in pediatric field were performed. 1. MIC of cefoxitin was compared with that of cefazolin and/or ampicillin for clinical isolates of Staphylococcus aureus (36 strains), Escherichia coli (35 strains), Klebsiella pneumoniae (34 strains) and Haemophilus influenzae (80 strains). MIC of cefoxitin against S. aureus was approximately 1-2 tubes higher than that of cefazolin. Many strains of E. coli and K. pneumoniae that showed high MIC to cefazolin were sensitive to cefoxitin. It is presumed that the results are due to the strong resistance of cefoxitin to beta-lactamase degradation. MIC of cefoxitin against H. influenzae was approximately 1-2 tubes lower than that of cefazolin, but approximately 4 tubes higher than that of ampicillin. 2. Serum level and urinary recovery rate of cefoxitin after one shot i.v. injection of 25 mg/kg were examined. The serum mean levels were 33.8 microgram/ml at 1/2 hour, 7.0 microgram/ml at 1 hour and 2.9 microgram/ml at 2 hours after the injection, respectively, and the drug was not detected in serum at 4 and 6 hours after the injection. The mean half-life of serum level was 27.1 minutes. The mean urinary recovery rate within 6 hours after injection was 96.0% and most of the drug were excreted into urine within 2 hours after the injection. 3. In order to evaluate clinical response, bacteriological response and side effects, cefoxitin was applied to 19 cases, i.e., 12 cases of either acute lobar pneumonia or acute bronchopneumonia, 2 cases of acute pyelitis, 1 case each of acute bronchitis, acute purulent tonsillitis, acute purulent arthritis, acute orbital phlegmon and acute buccal abscess. As for clinical response, the overall efficacy rate (the percentage of cases showed excellent and good efficacy) was 88.9%. As for bacteriological response, among the 13 strains which were determined or supposed to be causative organisms, i.e., 6 strains of Streptococcus pneumoniae, 2 strains of H. influenzae and 1 strain each of streptococcus pyogenes, alpha-Streptococcus, Enterococcus, E. coli and Neisseria sp., all strains were disappeared except for Enterococcus which was reduced by the treatment with cefoxitin. No side effect was observed in any case. Abnormalities of laboratory findings were observed in 3 cases, i.e., 1 case each of reduction of RBC and Hb, elevation of GOT and GPT and elevation of GPT, but all of them returned to normal following completion of the dosage term.
 ...
PMID:[Laboratory and clinical studies on cefoxitin in pediatric field (author's transl)]. 728 22

Azithromycin reaches high concentrations in phagocytic and other host cells, suggesting that they may transport this agent to specific sites of infection. Models of localized infection (Haemophilus influenzae middle ear infection in gerbils, Streptococcus pyogenes implanted contaminated paper disc and Streptococcus pneumoniae pneumonia in mice) that induced severe inflammatory response after challenge were used to explore this hypothesis. Animals were given a single 100 or 50 mg/kg po dose of azithromycin at various times from 2 to 120 h following introduction of a pathogen or sterile medium. When azithromycin was given during a period of little or no inflammation, there was marginal difference between concentrations found in infected or non-infected sites (bulla, disc, lung). However, when the compound was given during a period of inflammation, considerably higher drug concentrations were found in infected sites than in non-infected sites at 5-24 h after dosing (0.38-0.44 mg/c compared with 0.07-0.14 mg/L of bulla wash; 1.01-1.75 micrograms compared with < or = 0.01-0.03 microgram at the disc site; 1.72-5.28 mg/kg compared with 0.7-1.53 mg/kg of lung). When the observation periods were extended to include 48, 56 or 96 h after dosing, the ratio of azithromycin infection site concentration: serum concentration steadily increased with time in all model systems (middle ear, implanted disc and pneumonia), reflecting the maintenance of concentrations at the sites of infection, while serum concentrations declined. Bioassay of cell pellets and supernatants, obtained from pooled bulla washes of gerbils treated with azithromycin during a period of inflammation, revealed that cellular components accounted for about 75% of the azithromycin detected. These data show that increased azithromycin concentrations occur at sites of localized infection. This correlates with the presence of inflammation and is associated with the cellular components of the inflammatory response. Therefore, phagocytes may be important vehicles for delivering azithromycin to and sustaining azithromycin concentrations at sites of infection.
 ...
PMID:Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. 881 42

To provide optimal management for the child with community-acquired pneumonia, the clinician must take multiple factors into consideration. The etiology of pneumonia is difficult to determine and initial choice of therapy is based on the frequency of pathogens in various age groups, local antibiotic resistance patterns of the organisms, clinical presentation, and epidemiological data. Streptococcus pneumoniae and Haemophilus influenzae remain the most common bacterial pathogens outside the newborn period. Increasing numbers of multidrug-resistant strains of S pneumoniae in the United States and Europe, the decline in H influenzae type b because of current vaccination strategies, and increasing recognition of nontypeable H influenzae as etiologic agents of pneumonia have prompted reconsideration of the drug of choice. Amoxicillin and its derivatives or oral cephalosporins are the drugs of choice for initial therapy for mild to moderate disease. For severe disease or if beta-lactamase producing organisms are a concern, extended spectrum cephalosporins are indicated. Pneumococcal pneumonia unresponsive to penicillin therapy may warrant the use of extended spectrum cephalosporins or vancomycin. For older children in whom mycoplasma is a significant cause of pneumonia, the new macrolides have provided additional options for the clinician. Azithromycin and clarithromycin are efficacious, well tolerated, and require less frequent dosing intervals. The introduction of ceftriaxone, a third-generation cephalosporin with a broad spectrum of activity and prolonged half-life, allows once-a-day intramuscular therapy that can be administered on an outpatient basis. With the availability of parenteral outpatient therapy, hospital admission is no longer required for the treatment of most cases of serious community-acquired pneumonia.
 ...
PMID:Antimicrobial therapy of pneumonia in infants and children. 888 71

Cefodizime (CAS 69739-16-8, HR 221) is a new third-generation cephalosporin with pharmacokinetic properties that make it suitable for once-daily administration in the treatment of lower respiratory tract infections (LRTI). Ninety-nine adult hospitalized patients (66 males, 33 females, median age 57.5 years) received a once-daily injection of 2 g cefodizime for LRTI. Median treatment duration was 8 days. Forty-two patients received cefodizime intravenously and 57 intramuscularly. Indications for treatment were as follows; primary lobar pneumonia (n = 36), bronchopneumonia (n = 14), secondary pneumonia (n = 3), aspiration pneumonia (n = 5), acute exacerbation of chronic bronchitis (n = 21), and of bronchiectasis (n = 9) and acute purulent bronchitis (n = 11). General condition was good in 29 patients and poor in 58; 12 patients were critically ill. The following pathogens were isolated at baseline (source: bronchial secretions, sputum or blood): S. pneumoniae (n = 47), Haemophilus spp. (n = 17), M. catarrhalis (n = 6), Streptococcus spp. (n = 9), Staphylococcus spp. (n = 5), Klebsiella spp. (n = 4), Pseudomonas spp. (n = 1), A. calcoaceticus (n = 1) and anaerobic organisms (n = 7). Fifty-nine patients were evaluable for bacteriological response and 82 for clinical response. Bacteriological outcome was satisfactory in 29/30 patients having LRTI with parenchymal involvement (97%) and in 29/29 patients without parenchymal involvement (100%). Clinical cure was achieved in 41/43 evaluable patients with parenchymal involvement (95%) and in 37/39 patients without parenchymal involvement (95%) in the per-protocol analysis and in 54/58 patients (93%) and 37/41 patients (93%), respectively, in the clinical intention-to-treat analysis. Three of the patients with an unsatisfactory clinical response died of infection during the study. Cefodizime was well tolerated. Adverse reactions--all of mild intensity--were tachycardia, lumbalgia and dizziness, each occurring in one patient. Cefodizime 2 g once daily either i.m. or i.v. was effective in the treatment of lower respiratory tract infections in hospitalized patients.
 ...
PMID:Cefodizime once daily in the treatment of lower respiratory tract infections. 920 86

We retrospectively analyzed the severity, the mortality and the initial antimicrobial therapy in 195 patients with Streptococcus pneumoniae pneumonia (SPP). Of these, 59 (30.3%) patients had mixed pneumonia. In patients with mixed SPP, the three most frequent pathogens were influenza virus (27 patients), Haemophilus infuluenzae (14 patients), and Mycoplasma pneumoniae (8 patients). Of these, 21 (35.5%) patients were classified as severe or very severe according to the Japanese Respiratory Society diagnostic criteria among 59 patients of mixed SPP. Severe and very severe pneumonia was significantly associated with mixed infections (P = 0.018). The initial antimicrobial therapy was classified as beta-Lactam alone (113 patients), combination therapy including a beta-Lactam (72 patients), and a fluoroquinolone alone (10 patients). If we limit out study to mild-moderate pneumonia, initial combination therapy was significantly effective in patients with mixed SPP. Even in pneumonia caused by Streptococcus pneumoniae, further efforts to identify etiology are necessary.
 ...
PMID:[Clinical features of mixed infections in patients with Streptococcus pneumoniae pneumonia]. 1851 90


<< Previous 1 2